Sanjieke, a China-based vocational training services provider, has secured over 200 million yuan ($30 million) in its Series B+ and C rounds of funding, while Beijing Immunochina Pharmaceutical has raised ‘tens of millions of US dollars’ led by China Life Healthcare Investment.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
